Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 3, 2010, Pages 235-244

  Sikkema, Marjolein ^a   de Jonge, Pieter J F ^a   Steyerberg, Ewout W ^a   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Barrett's Esophagus; Dysplasia; Esophageal Adenocarcinoma; Incidence

Indexed keywords

BARRETT ESOPHAGUS; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; HUMAN; INCIDENCE; MEDICAL LITERATURE; PUBLICATION; REVIEW; SYSTEMATIC REVIEW;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 77349099667     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.10.010     Document Type: Review

References (77)

1. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25 (1994) 982-993
2. Hameeteman W., Tytgat G.N., Houthoff H.J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96 (1989) 1249-1256
3. van der Burgh A., Dees J., Hop W.C., et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39 (1996) 5-8
4. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1991) 1287-1289
5. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
6. van Soest E.M., Dieleman J.P., Siersema P.D., et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 54 (2005) 1062-1066
7. Lund O., Kimose H.H., Aagaard M.T., et al. Risk stratification and long-term results after surgical treatment of carcinomas of the thoracic esophagus and cardia. A 25-year retrospective study. J Thorac Cardiovasc Surg 99 (1990) 200-209
8. Wang K.K., and Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103 (2008) 788-797
9. Corley D.A., Levin T.R., Habel L.A., et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122 (2002) 633-640
10. Dulai G.S., Guha S., Kahn K.L., et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 122 (2002) 26-33
11. Conio M., Blanchi S., Lapertosa G., et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 98 (2003) 1931-1939
12. Hage M., Siersema P.D., van Dekken H., et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 39 (2004) 1175-1179
13. Provenzale D., Schmitt C., and Wong J.B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94 (1999) 2043-2053
14. Cameron A.J., Ott B.J., and Payne W.S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313 (1985) 857-859
15. Aldulaimi D.M., Cox M., Nwokolo C.U., et al. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 17 (2005) 943-950
16. Shaheen N.J., Crosby M.A., Bozymski E.M., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
17. Cook M.B., Wild C.P., Everett S.M., et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 (2007) 2090-2096
18. Moayyedi P., Burch N., Akhtar-Danesh N., et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 27 (2008) 316-320
19. Garside R., Pitt M., Somerville M., et al. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 10 (2006) 1-142 iii-iv
20. Anderson L.A., Murray L.J., Murphy S.J., et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 52 (2003) 1081-1084
21. Yousef F., Cardwell C., Cantwell M.M., et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 168 (2008) 237-249
22. Thomas T., Abrams K.R., De Caestecker J.S., et al. Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 26 (2007) 1465-1477
23. Chang E.Y., Morris C.D., Seltman A.K., et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 246 (2007) 11-21
24. Sutton A.J. Methods for meta-analysis in medical research (2000), John Wiley, New York, NY
25. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
26. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
27. Begg C.B., DuMouchel W., Harris J., et al. Publication bias in meta-analysis: A Bayesian data-augmentation approach to account for issues exemplified in the passive smoking debate-comments and rejoinders. Statistical Science 12 (1997) 241-250
28. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
29. Spechler S.J., Robbins A.H., Rubins H.B., et al. Adenocarcinoma and Barrett's esophagus. An overrated risk?. Gastroenterology 87 (1984) 927-933
30. Robertson C.S., Mayberry J.F., Nicholson D.A., et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 75 (1988) 760-763
31. Ovaska J., Miettinen M., and Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 34 (1989) 1336-1339
32. Miros M., Kerlin P., and Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 32 (1991) 1441-1446
33. Williamson W.A., Ellis Jr. F.H., Gibb S.P., et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 151 (1991) 2212-2216
34. Iftikhar S.Y., James P.D., Steele R.J., et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 33 (1992) 1155-1158
35. Attwood S.E., Barlow A.P., Norris T.L., et al. Barrett's oesophagus: effect of antireflux surgery on symptom control and development of complications. Br J Surg 79 (1992) 1050-1053
36. Ortiz A., Martinez de Haro L.F., Parrilla P., et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 83 (1996) 274-278
37. Wright T.A., Gray M.R., Morris A.I., et al. Cost effectiveness of detecting Barrett's cancer. Gut 39 (1996) 574-579
38. Komorowski R.A., Hogan W.J., and Chausow D.D. Barrett's ulcer: the clinical significance today. Am J Gastroenterol 91 (1996) 2310-2313
39. Sharma P., Morales T.G., Bhattacharyya A., et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 92 (1997) 2012-2016
40. Younes M., Ertan A., Lechago L.V., et al. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 42 (1997) 697-701
41. Katz D., Rothstein R., Schned A., et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 93 (1998) 536-541
42. Streitz Jr. J.M., Ellis Jr. F.H., Tilden R.L., et al. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 93 (1998) 911-915
43. Schoenfeld P., Johnston M., Piorkowski M., et al. Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's esophagus. Am J Gastroenterol 93 (1998) 906-910
44. Teodori L., Gohde W., Persiani M., et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 34 (1998) 257-263
45. Wilkinson S.P., Biddlestone L., Gore S., et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 13 (1999) 1205-1209
46. Macdonald C.E., Wicks A.C., and Playford R.J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 321 (2000) 1252-1255
47. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676
48. Srinivasan R., Katz P.O., Ramakrishnan A., et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 15 (2001) 519-524
49. Eckardt V.F., Kanzler G., and Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 111 (2001) 33-37
50. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48 (2001) 304-309
51. Rana P.S., and Johnston D.A. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance. Dis Esophagus 13 (2000) 28-31
52. Fitzgerald R.C., Saeed I.T., Khoo D., et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 46 (2001) 1892-1898
53. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285 (2001) 2331-2338
54. Parrilla P., Martinez de Haro L.F., Ortiz A., et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 237 (2003) 291-298
55. Murray L., Watson P., Johnston B., et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 327 (2003) 534-535
56. Hurschler D., Borovicka J., Neuweiler J., et al. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. Swiss Med Wkly 133 (2003) 507-514
57. Hillman L.C., Chiragakis L., Clarke A.C., et al. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 18 (2003) 526-533
58. Solaymani-Dodaran M., Logan R.F., West J., et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53 (2004) 1070-1074
59. Basu K.K., Pick B., and de Caestecker J.S. Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol 16 (2004) 171-175
60. Meining A., Ott R., Becker I., et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?. Gut 53 (2004) 1402-1407
61. Dulai G.S., Shekelle P.G., Jensen D.M., et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 100 (2005) 775-783
62. Murphy S.J., Dickey W., Hughes D., et al. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland. Eur J Gastroenterol Hepatol 17 (2005) 1029-1035
63. Oberg S., Wenner J., Johansson J., et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 242 (2005) 49-54
64. Gladman L., Chapman W., Iqbal T.H., et al. Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol 18 (2006) 271-276
65. Vieth M., Schubert B., Lang-Schwarz K., et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 38 (2006) 1201-1205
66. Sharma P., Falk G.W., Weston A.P., et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4 (2006) 566-572
67. Olithselvan A., Gorard D.A., and McIntyre A.S. A surveillance programme for Barrett's oesophagus in a UK general hospital. Eur J Gastroenterol Hepatol 19 (2007) 305-309
68. Gatenby P.A., Caygill C.P., Ramus J.R., et al. Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk. Dig Dis Sci 53 (2008) 1175-1185
69. Musana A.K., Resnick J.M., Torbey C.F., et al. Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol 103 (2008) 516-524
70. Martinek J., Benes M., Brandtl P., et al. Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study. Endoscopy 40 (2008) 711-716
71. Bani-Hani K., Sue-Ling H., Johnston D., et al. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol 12 (2000) 649-654
72. O'Connor J.B., Falk G.W., and Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94 (1999) 2037-2042
73. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92 (1997) 212-215
74. Solaymani-Dodaran M., Logan R.F., West J., et al. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol 100 (2005) 2616-2621
75. Jankowski J.A., Provenzale D., and Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 122 (2002) 588-590
76. Overholt B.F., Wang K.K., Burdick J.S., et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 66 (2007) 460-468
77. Pech O., Behrens A., May A., et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 57 (2008) 1200-1206